|
gptkbp:instanceOf
|
gptkb:drug
|
|
gptkbp:approvalYear
|
1994
|
|
gptkbp:ATCCode
|
A10BA02
|
|
gptkbp:bioavailability
|
50-60%
|
|
gptkbp:brand
|
gptkb:Riomet
gptkb:Fortamet
gptkb:Glucophage
gptkb:Glumetza
|
|
gptkbp:CASNumber
|
657-24-9
|
|
gptkbp:category
|
antidiabetic agent
hypoglycemic agent
|
|
gptkbp:contraindication
|
metabolic acidosis
renal impairment
|
|
gptkbp:discoveredBy
|
gptkb:Jean_Sterne
|
|
gptkbp:discoveredIn
|
1957
|
|
gptkbp:drugClass
|
biguanide
|
|
gptkbp:eliminationHalfLife
|
4-8.7 hours
|
|
gptkbp:excretion
|
renal
|
|
gptkbp:form
|
C4H11N5
|
|
gptkbp:foundIn
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:hasInChIKey
|
gptkb:XZWYZXLIPXDOLR-UHFFFAOYSA-N
|
|
gptkbp:hasSMILES
|
CN(C)C(=N)N=C(N)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
DB00275
|
|
gptkbp:indication
|
gptkb:type_2_diabetes_mellitus
|
|
gptkbp:isGeneric
|
true
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
decreases hepatic glucose production
increases insulin sensitivity
|
|
gptkbp:meltingPoint
|
223-226°C
|
|
gptkbp:metabolism
|
not metabolized
|
|
gptkbp:molecularWeight
|
129.164
|
|
gptkbp:name
|
gptkb:Metformin
|
|
gptkbp:origin
|
synthetic
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:proteinBinding
|
negligible
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1431
gptkb:DB00275
4091
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
gastrointestinal upset
lactic acidosis
|
|
gptkbp:status
|
approved
|
|
gptkbp:synonym
|
1,1-dimethylbiguanide
dimethylbiguanide
|
|
gptkbp:target
|
gptkb:AMP-activated_protein_kinase
gptkb:mitochondrial_respiratory_chain_complex_I
|
|
gptkbp:UNII
|
9100L32L2N
|
|
gptkbp:usedFor
|
gptkb:polycystic_ovary_syndrome
gptkb:gestational_diabetes
gptkb:prediabetes
|
|
gptkbp:bfsParent
|
gptkb:olmesartan
|
|
gptkbp:bfsLayer
|
7
|